Clinical Trial Update: Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating XL147 (SAR245408) in combination with trastuzumab or with paclitaxel and trastuzumab in metastatic breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)
• XL147 (SAR245408)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer, Breast Neoplasms | Phase 1, Phase 2 | Status: COMPLETED